• Molecular NamePemoline
  • SynonymPheniminooxazolidinone; Phenoxazole; Phenylisohydantoin; Phenylpseudohydantoin
  • Weight176.175
  • Drugbank_IDN/A
  • ACS_NO2152-34-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.4
  • pka10.5
  • LogD (pH=7, predicted)0.4
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.65
  • LogSw (predicted, AB/LogsW2.0)0.89
  • Sw (mg/ml) (predicted, ACD/Labs)3.99
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA64.68
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA medication used to treat attention-deficit hyperactivity disorder (ADHD) and narcolepsy.
  • Absorption_valueN/A
  • Absorption (description)Pemoline is rapidly absorbed from the gastrointestinal tract
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding50.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life10~18 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include insomnia, anorexia, stomach ache, skin rashes, increased irritability, mild depression, nausea, dizziness, headache, drowsiness, and hallucinations
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=500